Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1741-7015
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Tumor PKCδ instigates immune exclusion in EGFR-mutated non–small cell lung cancer ; volume:20 ; number:1 ; day:8 ; month:12 ; year:2022 ; pages:1-14 ; date:12.2022
BMC medicine ; 20, Heft 1 (8.12.2022), 1-14, 12.2022
- Urheber
-
Zuo, Yi-Han
Gao, Wei-Na
Xie, Ya-Jia
Yang, Sheng-Yong
Zhou, Jin-Tai
Liang, Hai-Hai
Fan, Xing-Xing
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12916-022-02670-0
- URN
-
urn:nbn:de:101:1-2023021809141943200833
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zuo, Yi-Han
- Gao, Wei-Na
- Xie, Ya-Jia
- Yang, Sheng-Yong
- Zhou, Jin-Tai
- Liang, Hai-Hai
- Fan, Xing-Xing
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Brain Metastasis from EGFR ‐Mutated Non‐Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up‐Regulates PDL1 and Promotes Immune Escape
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
Exosomes: a new perspective in EGFR-mutated lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Brain Metastasis from EGFR ‐Mutated Non‐Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up‐Regulates PDL1 and Promotes Immune Escape
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
Exosomes: a new perspective in EGFR-mutated lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
First-line treatment of EGFR-mutated nonsmall cell lung cancer : critical review on study methodology
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
Brain Metastasis from EGFR ‐Mutated Non‐Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up‐Regulates PDL1 and Promotes Immune Escape
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer
Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study